FDA approvals 2017
Gilead and PAHO announce milestone partnership to accelerate access to HIV pre-exposure treatment
The agreement will improve access to twice-yearly Lenacapavir across Latin America and the Caribbean
Gilead opens new research centre bringing together oncology, inflammation and research data science teams
The centre in California supports the company’s $32bn US investment
Roche and Nurix Therapeutics to partner in $2.3bn deal
The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology
Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma
This is the most common type of non-Hodgkin lymphoma worldwide
Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use
An estimated 1.2 million people in the US are currently living with the virus
CHMP recommends tablet formulation of BeOne’s targeted cancer drug Brukinsa
The new formulation would allow blood cancer patients to halve their daily pill intake
Gilead Sciences and Kymera enter oncology partnership worth up to $750m
The companies will focus on advancing Kymera’s oral molecular glue degrader programme
Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval
More than 100 people in the US were diagnosed with HIV every day in 2023
GSK’s Blenrep combinations approved by MHRA to treat multiple myeloma
Approximately 6,500 new cases of the blood cancer are diagnosed in the UK each year
J&J’s subcutaneous Darzalex regimen approved by EC for newly diagnosed multiple myeloma
More than 35,000 people in the EU were diagnosed with the blood cancer in 2022
Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer
Up to 160,000 people in the US are affected by polycythaemia vera
Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC
Primary biliary cholangitis affects approximately 163,000 people in Europe